Revamping The Fda Without The Stridency
Food & Drug Administration chief David A. Kessler was wary when Representative James C. Greenwood (R-Pa.) called to set up a June meeting. After all, Greenwood was steering through the House an FDA reform bill that Kessler had testified could put patients and consumers at risk. "You clearly have the votes to ram this through," Kessler pointed out. "Why negotiate with me?"
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.